本报告导读：公司积极推进“赢得分子”战略，新增项目持续增长，剥离爱尔兰疫苗工厂，优化资产配置，看好长期成长空间，维持“增持”评级。投资要点：维持“增持” 评级。公司公告2025年摩根大通医疗健康大会简报，维持2024 财年指引，预计2025 年营收将实现加速增长。考虑到投融资及地缘政治影响下客户需求扰动及新设施产能爬坡节奏，下调2024-2026 年EPS 预测为0.77/0.89/1.04 元（...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.